Skip to Content
Merck
  • Spontaneous tumorigenesis in mice overexpressing the p53-negative regulator Mdm4.

Spontaneous tumorigenesis in mice overexpressing the p53-negative regulator Mdm4.

Cancer research (2010-08-26)
Shunbin Xiong, Vinod Pant, Young-Ah Suh, Carolyn S Van Pelt, Yongxing Wang, Yasmine A Valentin-Vega, Sean M Post, Guillermina Lozano
ABSTRACT

High levels of the critical p53 inhibitor Mdm4 is common in tumors that retain a wild-type p53 allele, suggesting that Mdm4 overexpression is an important mechanism for p53 inactivation during tumorigenesis. To test this hypothesis in vivo, we generated transgenic mice with widespread expression of Mdm4. Two independent lines of transgenic mice, Mdm4(Tg1) and Mdm4(Tg15), developed spontaneous tumors, the most prevalent of which were sarcomas. To determine whether overexpression of Mdm4 also cooperated with p53 heterozygosity to induce tumorigenesis, we generated Mdm4(Tg1) p53(+/-) mice. These mice had significantly accelerated tumorigenesis and a distinct tumor spectrum with more carcinomas and significantly fewer lymphomas than p53(+/-) or Mdm4(Tg1) mice. Importantly, the remaining wild-type p53 allele was retained in most Mdm4(Tg1) p53(+/-) tumors. Mdm4 is thus a bona fide oncogene in vivo and cooperates with p53 heterozygosity to drive tumorigenesis. These Mdm4 mice will be invaluable for in vivo drug studies of Mdm4 inhibitors.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-MDM2 Antibody, clone 2A10, clone 2A10, from mouse